Astrazeneca (AZN) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval for Calquence, in combination with bendamustine and rituximab, as a treatment for adult patients with previously untreated mantle cell lymphoma.
The company said the recommendation was based on the results of a phase 3 trial, where the combination therapy demonstrated over 16 months of progression-free survival improvement compared with chemoimmunotherapy alone.
Astrazeneca also said no new safety signals were identified during the trial, and Calquence's safety and tolerability remained consistent with its known safety profile.
The company is currently evaluating Calquence as a single treatment and in combination with standard-of-care chemoimmunotherapy for the treatment of multiple B-cell blood cancers, according to the statement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。